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Abstract
Purpose Wheat bran fibre has a beneficial effect on gastrointestinal function, but evidence for wheat germ is scarce. Accord-
ingly, we evaluated the effects of daily intake of wheat germ on gastrointestinal discomfort and gut microbiota by adding 
wheat germ to refined (white) wheat bread, the most consumed bread type. We hypothesised that an improvement in the 
composition of refined bread could beneficially affect intestinal health without compromising consumers’ acceptance.
Methods Fifty-five healthy adults were recruited for a randomised, double-blind, crossover, controlled trial comprising two 
4-week intervention periods separated by a 5-week washout stage. During the first 4-week period, one group consumed wheat 
bread enriched with 6 g of wheat germ and the control group consumed non-enriched wheat bread.
Results Wheat germ-enriched bread was well-appreciated and the number of participants that demonstrated minimal gas-
trointestinal improvements after wheat-germ intake was higher than in the control arm. Importantly, intake of wheat germ-
enriched bread decreased the perceived gastrointestinal discomfort-related quality of life (subscale worries and concerns) 
over refined white bread. The improvements in the gastrointestinal function were accompanied by favourable changes in gut 
microbiota, increasing the number of Bacteroides spp. and Bifidobacterium spp.
Conclusions Adding wheat germ to industrially made white bread without altering sensory properties may promote a healthy 
gut bacterial microbiota and the gastrointestinal health.
Keywords Gastrointestinal discomfort · Gut microbiota · Bread · Wheat germ · Randomised controlled trial
Introduction
The human gastrointestinal tract is colonised by microor-
ganisms, mainly bacteria which have an important role in 
human metabolism and health. They are involved in the 
degradation of non-digestible food constituents/nutrients, 
production of secondary bile acids and the vitamins K and 
B, glucose and lipid metabolism as well as maturation and 
regulation of immune system [1–3]. In healthy adults, the 
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gut microbiota is in a “steady-state” equilibrium dominated 
by two major bacterial phyla Bacteroidetes and Firmicutes, 
and in minor extent by Actinobacteria (e.g., Bifidobacte-
rium), Verrucomicrobia (Akkermansia), and Proteobacteria 
(Escherichia) [4]. Changes in the composition, diversity, 
and richness of the gut microbiota can compromise its func-
tion, potentially leading to a disease-state. Indeed, several 
recent systematic reviews have demonstrated that patients 
diagnosed with functional gastrointestinal disorders, includ-
ing irritable bowel syndrome (IBS), had alterations in gut 
microbiota characterised by a decrease in bacterial diversity 
and proliferation of potential pathogenic bacterial such as 
Escherichia coli [5, 6]. Diet is the major modifiable factor 
of human gut microbiota [7]. Numerous dietary intervention 
studies have been conducted to potentiate the enrichment of 
beneficial gut bacteria [5, 8]. A “substrate that is selectively 
utilized by host microorganisms conferring a health benefit” 
is called prebiotic [9]. However, outcomes are frequently 
controversial because of inter-individual variability in the 
response to a specific dietary intervention [10–12]. Because 
of that, some authors that defend personalised diets [11–13]. 
Nonetheless, the effect of food with beneficial ingredients 
for human health needs to be researched to be considered as 
general or specific dietary recommendations.
Whole grains contain bran and germ that are considered 
to be the healthy ingredients of whole grains. The germ 
is the definition for the embryonic axis and the scutellum 
of the seed; germ is rich in bioactive compounds such as 
α-linolenic acid, oligosaccharides, flavonoids, phytosterols, 
and vitamins (namely, thiamine, riboflavin, tocopherols, 
tocotrienols, and phylloquinone) [14]. The physiological 
effect of bran (designation for the outer layer of the grains) in 
gastrointestinal function has been demonstrated and health 
claims regarding these physiological effects were approved 
for wheat bran fibre in the European Union [15]. The dietary 
fibres mostly present in bran reduce intestinal transit time 
while increasing faecal bulk and water retention in the colon 
that, altogether, change stool characteristics and defaecation 
frequency [16–19]. The evidence suggests that dietary fibres 
confer most of their health benefits indirectly through the 
metabolic products derived from fibre’s fermentation by the 
gut microbiota [20–23]. Regarding germ, an in vitro study 
using a gastrointestinal model that compared different com-
mercial prebiotic products showed that a wheat-germ prepa-
ration efficiently enhanced the proportion of bifidobacteria 
from 15 to up to 24% of total bacteria in the faecal mat-
ter [24]. Likewise, a randomised clinical trial involving 32 
healthy subjects, demonstrated that daily ingestion of wheat 
germ as a dietary supplement increased the number of gut 
bifidobacteria and lactobacilli, but only in individuals with 
low basal levels [25].
Considering the potential of wheat germ to improve the 
microbiota of healthy individuals and knowing that gut 
microbiota can affect gastrointestinal function, we hypoth-
esised that wheat germ may improve the gastrointestinal 
function. Improving the gastrointestinal health has an impor-
tant impact on the quality of life [2, 26, 27], and impor-
tantly, one-third of the worldwide population has one type 
of gastrointestinal discomfort, among which the most com-
mon are bloating and constipation [28]. Since a reduction 
in gastrointestinal discomfort is considered an indicator of 
improved gastrointestinal function [27], we designed a ran-
domised clinical trial to evaluate the impact of daily intake 
of wheat germ on the gastrointestinal discomfort and the 
gut microbiota of healthy volunteers. Thus, to introduce the 
wheat-germ intervention in the diet, a refined wheat bread 
supplemented with 6 g of wheat germ was produced and 
its effects were compared with regular refined wheat germ, 
i.e., without supplementation (hereafter control bread). We 
chose bread as a vehicle for the intake of germ because of 
its important role in the human diet. Bread contributes to 
the 10% of daily caloric intake and it is also an important 
source of carbohydrate [12]. To understand the impact of 
wheat-germ intervention on daily life, we used a validated 
self-reported measurement of health-related quality of life 
(PAC-QOL) designed to evaluate patient’s assessment of 
constipation. This outcome is crucial to infer the validity 
of wheat-germ intake intervention in terms of benefits for 
human health. Our study is the first clinical trial that inves-
tigates the effect of wheat germ on gastrointestinal health.
Materials and methods
Study participants and design
The clinical trial was conducted from June 2015 to Octo-
ber 2016 after obtaining approval from the Health Ethics 
Committee of the University Hospital Center of São João 
and the Ethics Committee of the Faculty of Medicine of the 
University of Porto (07/2015). The study was conducted in 
accordance with the ethical principles of the Declaration of 
Helsinki and followed the Good Clinical Practice guidelines. 
Written informed consent was obtained from all participants 
before enrolment. The present study was registered in the 
ClinicalTrials.gov database (NCT02405507).
The detailed study protocol and baseline characteristics of 
the participants were previously published [29, 30]. Briefly, 
we report here a randomised, double-blind, crossover, con-
trolled clinical trial. This trial comprised a 15-week follow-
up with a 2-week run-in step, two crossover interventions 
of 4 weeks/each, separated by a 5-week washout period 
(Fig. 1). Fifty-five participants were recruited. The exclu-
sion criteria included (1) bowel frequency lesser than twice 
per week, (2) use of medication or dietary supplements that 
influenced the intestinal microbiota, (3) use of prebiotics 
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and probiotics, and (4) change of dietary habits 4 weeks 
before recruitment. Moreover, participants were instructed 
not to change their physical activity and dietary habits and 
not to consume any food or dietary product supplemented 
with germ before and during the follow-up. The participants 
recruited for this study were non-smokers, had no gastric 
bypass surgery, and were free of any chronic or digestive 
diseases with relevant effect on the gastrointestinal system 
Screened for eligibility
(n = 68)
Ineligible for inclusion (13)
• Did not meet inclusion criteria (n = 1)
• Met exclusion criteria (n = 6)





• Time conflict (n= 1)
Run-in
Dropped out
• Unspecified reasons (n = 2)
• Planning pregnancy (n=1)
Washout
Dropped out
• Lifestyle changes (cigarette smoking) (n = 1)
• Unspecified reason (n =1)





(n = 27) (n = 25)
(n = 26) (n = 25)
Control
Dropped out (n = 0)
Intervenon
Dropped out
• Unrelated Illness (n = 1)
Control
Dropped out (n = 0)
Analysis
Completed initial assessment (n = 52)
Completed intervention and were compliant with the daily
bread intake (n = 47)
(n = 23) (n = 25)
(n = 23) (n = 24)
Follow-up visit I: after 
2-week run-in period
Follow-up visit II: after 
4-week intake period
Follow-up visit III: after 
5-week washout period




















Fig. 1  Overview of study design and participants flow (adapted from Moreira-Rosário et al. [30])
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or on visceral motility, including functional bowel disor-
ders such as irritable bowel syndrome (IBS). None of the 
participants was medicated for digestive symptoms such as 
anti-spasmodic, laxatives, and anti-diarrheic drugs or other 
digestive auxiliaries.
Participants were randomly divided into two groups (ratio 
1:1): intervention 1 consisted in consuming daily refined 
wheat bread (100 g) supplemented with 6 g of wheat germ, 
while intervention 2 comprised the daily intake of refined 
wheat bread (100  g) without any supplementation (the 
control arm). The formula for preparing the wheat germ-
enriched bread was developed so as to mask the texture, 
volume, and flavour of the final product, whose formula-
tion is described in our previous work [30]. Thus, control 
and wheat-germ-supplemented bread were indistinguish-
able, which allowed double blinding of the participants 
and researchers. The detailed description of the nutrient 
composition of both breads is presented in Supplemental 
Table 1. The unblinding occurred after statistical analysis. 
Compliance with the study protocol was monitored daily 
using self-reported questionnaires.
The outcome evaluations were performed at the end of 
each stage: (T1) run-in; (T2) intervention 1; (T3) wash-
out; and (T4) intervention 2. The outcomes measured were 
grouped in two categories: (a) CVD risk factors and (b) gas-
trointestinal function. The results regarding the outcomes 
related to CVD risk markers are discussed separately [30]. 
Herein, we report the outcomes of the gastrointestinal func-
tion. We measured the gastrointestinal discomfort associ-
ated with constipation as a primary outcome. The secondary 
outcomes included (i) quality of life with regard to consti-
pation, (ii) stool frequency and consistency, (iii) intestinal 
microbiota, and (iv) psychological stress.
Stool collection
One faeces sample was collected up to 72 h before the end 
of each period (T1, T2, T3, and T4) and stored in a tube 
containing 3 ml RNAlater Solution (Sigma-Aldrich) to pre-
serve the DNA integrity. Samples were kept at − 80 °C until 
DNA extraction.
DNA extraction from stool samples
DNA was extracted from the stool samples using NZY Tis-
sue gDNA Isolation Kit (NZYtech). Approximately 200 mg 
of faeces were homogenised in 1 ml TE buffer, centrifuged 
and the supernatant discarded. The remaining pellet was 
resuspended in 350 µl of buffer NT1 and incubated at 95 °C 
during 10 min for promoting bacterial cell lysis. Samples 
were spanned and the pellet was discarded. 25 µl of Pro-
teinase K solution (NZYtech) was added to the superna-
tant and the mixture was incubated at 70 °C for 10 min. 
RNA contamination was removed by subsequent incubation 
with 400 µg RNase A (NZYtech) at room temperature dur-
ing 15 min. After this, the DNA extraction was performed 
according to the manufacturer’s instructions. The purified 
faecal DNA was quantified by measuring A260. The A260/A280 
ratio was used to estimate the purity of the extracted RNA 
which should be between 1.8 and 2.0.
Gut microbiota quantification by real‑time PCR
The quantification of genomic DNA was carried out using 
the LightCycler 96 Real-Time PCR system (Roche) with the 
FastStart Essential DNA Green Master quantification assay 
(Roche), following the manufacturer instructions. Each 20 
μl reaction contained 20 ng of total faecal DNA and specific 
primers for 16S ribosomal RNA gene, which is a molecu-
lar marker to genus/specie identification. The quantitative 
PCR reactions were performed using the thermal cycling 
parameters default conditions; the annealing temperature 
was primer-specific (Supplemental Table 2). After ampli-
fication, reactions were checked for the presence of non-
specific products through dissociation curve analysis.
For bacterial quantification, tenfold serial dilutions of 
genomic DNA extracted from ATCC bacterial reference 
strains were constructed for each 16S rRNA gene (Sup-
plemental Table 2). The amount of DNA present per 20 µl 
reaction was converted into copy number based on bacterial 
genome size (base pairs) and the 16S rRNA gene number per 
genome. The number of copies was determined by extrapola-
tion, using the specific standard curve from validated refer-
ence strains, and normalised to the amount of faecal DNA 
and amount of faeces in grams. The quantification values are 
expressed in  log10 copies/g faeces and should be interpreted 
in terms of relative amounts.
Recording of gastrointestinal discomfort
Gastrointestinal discomfort was self-evaluated every 
2 weeks using the validated Patient Assessment of Consti-
pation Symptoms (PAC-SYM) and Patient Assessment of 
Constipation Quality-of-Life (PAC-QOL) questionnaires. 
The PAC-SYM includes 12 constipation-related symptoms 
grouped into three subscales related to abdominal, stool, and 
rectal symptoms. This questionnaire is rated on a 5-point 
scale, from 0 (no symptom) to 4 (very severe), aiming to 
measure the severity of gastrointestinal discomfort over the 
previous 2 weeks. In parallel, the participants evaluated the 
impact of gastrointestinal discomfort-related symptoms on 
health-related quality of life using a validated self-reported 
quality-of-life questionnaire (PAC-QOL). The PAC-QOL is 
composed of 28 items grouped into four subscales related 
to physical discomfort, psychosocial discomfort, worries 
and concerns, and satisfaction. This validated self-reported 
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questionnaire is rated on a 5-point scale, from 0 to 4 (where 
0 = at no time/not at all, 4 = all the time/extremely), and is 
used over a 2-week recall period; scores of items 18 and 
25–28 (satisfaction subscale) were reversed meaning as 
stated in the guidelines. A reduction in PAC-SYM and 
PAC-QOL scores (total or subscale) corresponds to an 
improvement in symptoms. Moreover, a − 0.5 reduction cor-
responds to the smallest level of change in a self-reported 
outcome score that is perceived as an improvement [31]. 
Cultural adaptation and linguistic validation of the PAC-
SYM and PAC-QOL for Portugal were performed by the 
Mapi Research Trust (France).
Recording of stool parameters
During the 15-week follow-up period, the participants 
reported all bowel movements according to the Bristol Stool 
Form Scale (7-point scale) in daily self-reported question-
naires. Based on this information, the average stool con-
sistency (sum of Bristol Stool Form Scales divided by the 
number of stools) and the average stool frequency (number 
of stools divided by the number of days of diary recording) 
were assessed.
Confounding variables
Psychosocial factors such as psychological stress are a well-
documented variable known to influence gut physiology and 
gastrointestinal symptoms [32]. For these reasons, the effect 
of wheat germ on gastrointestinal discomfort was controlled 
for psychological stress. A psychometric assessment was 
carried out every 4 weeks using the validated Perceived 
Stress Scale (PSS). This 13-item self-reported questionnaire 
measures the degree to which situations in a person’s life 
are appraised as stressful. Cultural adaptation and linguistic 
validation of the PSS for Portugal were implemented by Pais 
Ribeiro and Marques [33].
Statistical analysis
Intervention effects were calculated as the difference 
between the change during each 4-week intervention period 
and the change during the 4-week control period. The 
change in gastrointestinal outcomes (PAC-SYM, PAC-QOL, 
stool frequency, and consistency) was the difference between 
the last 2 weeks of first intervention period and the 2 weeks 
of run-in period or the last 2 weeks of the second interven-
tion period and the last 2 weeks of washout period. Total 
score and subscale scores of self-reported questionnaire 
(PAC-SYM, PAC-QOL and PSS) were computed based on 
non-missing item responses. Whenever more than 50% of 
items were missing the total scale or subscale score were 
not calculated and were designated as ‘missing’. The same 
procedure was performed when more than 7 daily records of 
stool frequency or consistency were missing; the average of 
the 2-week interval was not calculated and, therefore, was 
designated as ‘missing’. The proportion of participants with 
a minimal clinical improvement in PAC-SYM and PAC-
QOL scores was calculated. A reduction of half a point in 
total and subscales scores was used, since it corresponds 
to minimal clinical improvement according with previous 
validation studies [31, 34]. We compared the proportion 
of participants with a minimal clinical improvement after 
a 4-week intervention period with the control period using 
the McNemar test.
The sample size was estimated taking into account the 
primary outcome that required the highest number of par-
ticipants. For that, we calculated the sample size for each 
individually primary outcome, as described in the proto-
col manuscript [29]. To detect a 0.35 difference and an SD 
of 0.75 in the PAC-SYM total score, with 80% power and 
95% confidence level, the estimated sample size was 40 
participants.
A linear mixed model for repeated measures with com-
pound symmetry as covariance structure was used to deter-
mine whether the intervention effects were statistically 
significant. Compound symmetry was used instead of the 
autoregressive or unstructured structure, because it resulted 
in the best fit according to a likelihood ratio test. Interven-
tion, period, and sequence were included as fixed effects var-
iables. To account for the between-subjects variability and to 
adjust any non-specific differences, subjects were included 
as random effects. We also included intervention–sequence 
interaction as a fixed effect in the model to assess poten-
tial carryover effects. When carryover was significant, we 
reported the first period in the analysis, following Pocock’s 
recommendations [35].
Statistical analysis was performed using the SPSS version 
23 software (SPSS Inc.). Numerical data are expressed as 
mean ± SD and treatment effects with 95% CI. Statistical 
significance was set at a two-sided P value of 0.05. However, 
because we had multiple primary outcomes, we decided to 
perform an adjustment for multiple comparison; thus, the 
type 1 error associated with any individual variable differ-
ence took into account all comparisons performed and were 
ruled significant after adjusting for the overall false discov-
ery rate, using the Benjamini–Hochberg procedure (with 
q* = 0.05) [36].
Results
Participants
Sixty-eight volunteers were screened and assessed for eli-
gibility to participate in our study. After initial assessment, 
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55 participants were enrolled in the study; 39 women and 16 
men, with a mean age of 33 years (range 18–59 years), and a 
BMI between 19 and 38 kg/m2 (37 with normal weight, 14 
overweight and 4 obese). This sample is representative of 
a healthy population. Eight participants dropped out in the 
course of the study: the first six declined to participate and 
the las last two withdrew because of unrelated illness (gas-
troparesis and pneumonia). Besides that, no other adverse 
events were reported throughout the study.
Compliance and confounders
Because of the absence of a biomarker for wheat-germ 
intake, the compliance was measured through self-reported 
daily questionnaires. The analysis of dietary intake 
data showed a good compliance with the study protocol 
(92.1% ± 9.3), and moreover, compliance was comparable 
between interventions (wheat germ: 92.2% ± 11.1; control: 
92.0% ± 10.0; P = 0.920). Indeed, the control bread and the 
wheat germ-enriched bread were well-appreciated by the 
participants, and more importantly, both products have iden-
tical sensory properties (Supplemental Table 3). However, 
the two intervention breads differ in terms of nutritional 
composition. The addition of 6 g of wheat germ in 100 g 
of refined wheat bread increased the amounts of protein, 
dietary fibre, total phytosterols, and alpha-linolenic acid in 
the wheat germ-enriched bread. On the other hand, the con-
tent of carbohydrate and starch was higher in the control, 
while the content of fat and energy remained similar in both, 
intervention and control bread.
To control a potential bias due to psychological stress, a 
self-reported questionnaire evaluating individual perceived 
stress was used. This confounding variable was measured 
during run-in and intervention stages. Results from the 
Perceived Stress Scale (PSS) questionnaire showed no 
significant differences within wheat-germ intake group 
(P = 0.572), within the control (P = 0.179) or between groups 
(P = 0.211) during the study.
Gastrointestinal discomfort associated 
with constipation
Gastrointestinal discomfort was individually measured 
through the PAC-SYM. In this 5-point scale of symptoms, 
a score of 0 corresponds to the absence of symptoms, 1 to 
mild, 2 to moderate, 3 to severe, and 4 to very severe symp-
toms. The impact of constipation symptoms on the quality 
of life was evaluated using PAC-QOL. Descriptive statistics 
for the PAC-SYM and PAC-QOL scores are presented in 
Tables 1 and 2. The means of PAC-SYM and PAC-QOL 
overall and subscales scores varied between 0 and 1 at base-
line and during the study, as expected for a healthy popula-
tion. The exception is the PAC-QOL satisfaction subscale 
that was higher than 1.
The differences observed in the PAC-SYM question-
naire are not statistically significant (P > 0.05) when com-
paring baseline with post-intervention or when comparing 
wheat-germ intake with control (Table 1). The number of 
participants that improved ≥ 0.5 in the PAC-SYM score was 
analysed. Thus, despite not statistically significant, consider-
ably more participants (14%, 7/50; P = 0.063) that consumed 
wheat germ-enriched bread during 4 weeks improved half 
a point or more in the total PAC-SYM score when com-
pared with the same period of control bread intake (2%, 
1/48) (Fig. 2). Evaluation of the defecation frequency and 
stool consistency using the Bristol scale does not suggest 
any effect associated with wheat-germ intake (Supplemental 
Table 4).
Table 1  Effect of 4-week intake of wheat germ on gastrointestinal discomfort associated with constipation
The gastrointestinal discomfort was self-evaluated using the validated Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire
a Mean ± SD. PAC-SYM Patient Assessment of Constipation Symptoms
b Intervention effects were analysed using linear mixed model for repeated measures with compound symmetry as covariance structure
Wheat germ-enriched bread Control bread Effect of wheat  germb




















0.49 ± 0.43 0.55 ± 0.61 0.393 0.46 ± 0.42 0.46 ± 0.52 0.976 0.07 (− 0.14, 0.27) 0.505
 Stool symptoms 
(5 items)
0.61 ± 0.66 0.52 ± 0.58 0.187 0.57 ± 0.58 0.50 ± 0.59 0.175 − 0.01 (− 0.17, 0.14) 0.843
 Rectal symp-
toms (3 items)
0.32 ± 0.68 0.28 ± 0.43 0.637 0.20 ± 0.40 0.22 ± 0.40 0.566 −0.06 (− 0.24, 0.13) 0.531
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Concerning the PAC-QOL questionnaire, the 4-week 
consumption of wheat germ-enriched bread demonstrated 
a positive effect in the worries and concerns subscale 
(− 0.16 [− 0.27; − 0.05], P = 0.007) (Table 2). The effects 
measured in the overall, physical, and psychosocial dis-
comfort subscales, indicate an improvement tendency 
although not statistically significant. This tendency is sim-
ilar to the one observed in the analysis of the proportion of 
participants with a minimal clinical improvement (Fig. 3).
Gut microbiota
Specific genera or species that have been reported as benefi-
cial for human health were selected for analysis by real-time 
PCR. Shifts in the number of copies of 16S rRNA genes 
for each target bacterial specie or genus were analysed in 
the faecal microbiota at baseline and after each intervention 
period. The statistical analyses of intervention–sequence 
interaction indicated the presence of carryover effects in a 
considerable part of the microbiota data, although our study 
Table 2  Effect of 4-week intake of wheat germ on the quality of life regarding gastrointestinal discomfort associated with constipation
The impact of gastrointestinal discomfort-related symptoms were self-evaluated using the validated Patient Assessment of Constipation Quality-
of-Life (PAC-QOL) questionnaire
a Mean ± SD. PAC-QOL Patient Assessment of Constipation Quality of Life
b Intervention effects were analysed using linear mixed model for repeated measures with compound symmetry as covariance structure
Wheat germ-enriched bread Control bread Effect of wheat  germb



















 Overall score 0.57 ± 0.47 0.54 ± 0.49 0.488 0.51 ± 0.40 0.58 ± 0.54 0.178 − 0.10 (− 0.23, 0.03) 0.130
 Satisfaction (5 
items)












0.46 ± 0.48 0.38 ± 0.52 0.084 0.35 ± 0.41 0.44 ± 0.56 0.109 − 0.16 (− 0.27, − 0.05) 0.007
0% 5% 10% 15% 20% 25%
     Overall score
     Abdominal symptoms
     Stool symptoms
     Rectal symptoms








Fig. 2  Percentage of participants with minimal clinical improvement 
after 4-week daily intake of wheat germ-enriched bread and control 
bread. Score changes of half a point correspond to minimal clinical 
improvement. PAC-SYM Patient Assessment of Constipation Symp-
toms
0% 5% 10% 15% 20% 25%
     Overall score
     Satisfaction
     Physical discomfort
    Psychosocial discomfort
     Worries and concerns









Fig. 3  Percentage of participants with minimal clinical improvement 
after 4-week daily intake of wheat germ-enriched bread and control 
bread. Score changes of half a point correspond to minimum impor-
tant difference (improvement). PAC-SYM Patient Assessment of Con-
stipation Symptoms
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design included a 5-week washout period between the two 
intervention periods, aiming to minimise the risk of a car-
ryover effect between interventions in period 1 and period 2. 
Thus, the crossover design was not considered for evaluat-
ing gut microbiota and only the first period was analysed. 
We emphasise that no significant differences were found 
between parallel groups in terms of subject characteristics 
(sex, age, weight, or BMI; Supplemental Table 5) or in base-
line microbiota composition.
Our results show within-group differences in the intesti-
nal bacterial microbiota of healthy volunteers that ingested 
wheat-germ bread (Fig.  4). Accordingly, we detected 
an increase in the number of Bacteroides spp. chang-
ing from 9.51 ± 1.11 to 9.96 ± 0.73  log10 copies/g faeces 
(P = 0.004). Likewise, the number of Bifidobacterium spp. 
rose from 10.03 ± 0.89 to 10.37 ± 0.88  log10 copies/g fae-
ces (P = 0.008). Other bacteria known as beneficial such 
as Clostridium leptum and Roseburia spp. also increased, 
although the differences detected are not statistically sig-
nificant. In general, the total number of bacteria increased 
after the 4-week intervention with wheat germ-enriched 
bread from 10.71 ± 0.46 at baseline to 10.92 ± 0.54  log10 
copies/g faeces after intervention (P = 0.070). A relevant 
exception is the Gram-negative coliform Escherichia coli 
that remains unchanged (from 7.95 ± 0.90 to 7.93 ± 1.22 
 log10 copies/g faeces; P = 0.925); however, a tendency of 
reduction is observed (− 0.75; P = 0.084) when the data are 
stratified by BMI and only participants with normal BMI 
are considered (N = 31). In contrast, the intake of control 
bread apparently increased the number of E. coli from 
7.92 ± 1.05 to 8.22 ± 0.88  log10 copies/g faeces (P = 0.248) 
that, despite not being statistically significant, demon-
strates an opposite tendency compared with the ingestion of 
wheat germ-enriched bread. Another effect of control bread 
was the likely decrease of Akkermansia muciniphila from 
6.73 ± 2.16 to 6.51 ± 2.26  log10 copies/g faeces (P = 0.249) 
in opposition to wheat-germ intake that had an increase 
effect of 0.71 (P = 0.137).
Discussion
In this study, we found minimal differences in gastrointes-
tinal function between the dietary interventions with wheat 
germ-enriched bread and refined wheat bread (control). The 
4-week daily intake of wheat germ is very well tolerated by 
Fig. 4  Composition of the intestinal microbiota expressed as  log10 
copies/g faeces (mean ± SEM) of the study population at specie or 
genus level (Clostridium leptum, Lactobacillus spp., Roseburia spp., 
Bacteroides spp., Bifidobacterium spp., Akkermansia muciniphila and 
Escherichia coli) and phylum level (Firmicutes and Bacteroidetes). 
Fimic./Bact. ratio Firmicutes/Bacteroidetes ratio. Bifido./E. coli ratio 
Bifidobacteria/Escherichia coli ratio. Only the first period was used 
in the analysis due the existence of carryover effects. The statistically 
significant differences between baseline and 4 weeks were compared 
using the paired t test (*P < 0.05)
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healthy volunteers, and in general, more participants tend 
to demonstrate minimal clinical improvement in PAC-SYM 
and PAC-QOL (total and subscales) after wheat-germ-
enriched-bread ingestion than in the control arm. This dif-
ference is larger in the PAC-SYM total score (14% with 
wheat-germ intake versus 2% with control bread; P = 0.063). 
Importantly, we demonstrated an improvement in the per-
ceived gastrointestinal discomfort-related quality of life in 
the subscale “worries and concerns”, after the 4-week intake 
of wheat germ regarding control (P = 0.007). These results 
were unlikely to be influenced by psychological factors (con-
founding variable) (Supporting Information Table S4).
The gastrointestinal tolerability and functionality of 
wheat germ could be explained by favourable changes on the 
gut bacterial microbiota (Fig. 3 and Supplemental Table 6). 
Two different genera increased their abundance after wheat-
germ intake: Bifidobacterium spp. and Bacteroides spp. 
Bifidobacteria are resident microbiota members which are 
known as probiotics [37] and their presence is associated 
with gut health. Recent data suggest that these bacteria can 
modulate T-cell responses reducing inflammation [38] and 
lower bifidobacteria abundance occurs in multiple inflam-
matory diseases including IBD. Lower levels of Bacteroides 
spp. are also associated with IBD by a mechanism similar to 
bifidobacteria [39]. Bacteroides spp. are part of the human 
gut microbiota well known for their ability to breakdown 
a wide variety of indigestible polysaccharides; they pro-
vide benefits to the human gut [40, 41]. Moreover, our data 
suggest an increase of Clostridium leptum, Akkermansia 
muciniphila and Roseburia spp. after wheat-germ intake, 
and these bacteria are known to exert positive effects on gut 
health [42]. Importantly, all alterations are not dependent on 
the initial microbiota composition of each subject, as previ-
ously observed by Matteuzzi et al. [25]. The changes herein 
reported were observed in the wheat-germ period, but not 
detected when the control and the wheat-germ groups were 
compared. However, the within-group comparison is scien-
tifically limited. Thus, we conclude that wheat-germ intake 
may contribute to establish a healthy bacterial microbiota, 
unveiling wheat germ as a promising valuable prebiotic, 
which needs to be further investigated.
Likewise, we also detected relevant changes induced by 
the control bread that, despite not being statistically sig-
nificant, should be highlighted, because they are clinically 
important. Thus, in opposition to wheat germ-enriched 
bread, the intake of refined bread without wheat germ seems 
to decrease the number of A. muciniphila while increasing 
Escherichia coli abundance. These changes are suggestive 
of a poor gut health. E. coli is belongs to the gut microbiota, 
whose high abundance is frequently associated with colo-
rectal tumours [43], and A. muciniphila is associated with a 
healthier metabolic status and better clinical outcomes after 
calorie restriction in overweight/obese adults [44]. Some 
authors suggest that A. muciniphila can function as a diag-
nostic or prognostic tool to predict the potential success of 
dietary interventions [45]. The microbiota changes observed 
after control bread intake should be explored in the future, 
because for the first time, it is suggested that refined wheat 
bread could have a negative effect on gut microbiota. Clari-
fying this link is relevant in terms of public health, since 
refined bread is preferred by the majority of the populations, 
consumed more frequently, and in more occasions [46, 47].
In this study, the subjects were healthy volunteers with 
minimal gastrointestinal discomfort symptoms, as revealed 
by the PAC-SYM and the PAC-QOL overall and subscales 
score means at baseline. They had four times less gastro-
intestinal discomfort symptoms than the IBS patients or 
subjects with reduced bowel movements and gastrointes-
tinal discomfort [48, 49]. Because of that, the number of 
participants enrolled should be higher than the number ini-
tially estimated to detect statistically significant differences. 
At the moment, this study was carried out, clinical trials 
evaluating the gastrointestinal discomfort in healthy sub-
jects having PAC-SYM as an outcome were not available. 
For that reason, our sample size calculations were based on 
studies involving subjects with symptoms of gastrointestinal 
discomfort. This limitation prevents extensive conclusions 
regarding wheat germ-enriched-bread effect on gastrointes-
tinal function and discomfort. Regarding the effect of wheat 
germ on the bacterial microbiota, the presence of carryover 
effects did not allow us to take the most advantage of the 
crossover design, and therefore, the washout period should 
be longer than 5 weeks. Other study limitations include diet-
induced bias on the results reported. Despite the subjects 
were informed and asked not to change their dietary hab-
its during the study, diet was not monitored to avoid what 
could be seen as an additional psychological pressure for the 
participants; and this is another potential confounding vari-
able. Finally, the differences measured at the bacterial genus 
level can be interpreted in terms of changes in the diversity 
within each target genus or changes in the number of species 
already present at baseline. This is a limitation imposed by 
real-time PCR methodology.
In conclusion, adding wheat germ to refined wheat bread 
seems to promote a healthy gut bacterial microbiota which 
could be beneficial for gastrointestinal health. Participants 
that consumed wheat germ-enriched bread reported bet-
ter health-related quality of life concerning worries and 
concerns. Our results indicate that wheat germ is able to 
overcome resilience of gut microbiota and may promote 
the growth of beneficial genera, while it has a protective 
role against proliferation of potential pathogenic detrimen-
tal bacterial species such as E. coli. Indeed, the partici-
pants that ingested wheat germ-enriched bread had a high 
bifidobacteria/E. coli ratio that is considered an important 
indicator of gut microbiota equilibrium and health. The 
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effect of wheat germ in the bifidobacteria/E. coli ratio was 
0.10 [(− 0.01; 0.21); P = 0.073]. Accordingly, adding wheat 
germ to regular refined bread is an elegant strategy to over-
come the consumers’ preference for white bread and in this 
way, promoting better public health. In the future, it will 
be important to understand whether wheat-germ-induced 
changes on the gut bacterial microbiota are temporary or 
can be maintained by continuing the intake of this cereal 
grain ingredient.
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